<DOC>
	<DOCNO>NCT03102177</DOCNO>
	<brief_summary>This study prospective , single-center , open-label , non-randomized , pharmacokinetic study use stable isotope carbon-13 label levothyroxine</brief_summary>
	<brief_title>Effect Age , Weight Sex Levothyroxine Pharmacokinetics</brief_title>
	<detailed_description>Setting The study conduct clinical research unit academic medical center . Participants Adults age treat levothyroxine hypothyroidism study . Interventions A single dose 13C- LT4 administer hypothyroid subject take levothyroxine replacement . Main Outcomes Measures Eighteen serial plasma sample collect . One sample obtain 13C- LT4 dose remainder 312-hour period post-dosing . 13C- LT4 concentration quantify use validate liquid chromatography tandem mass spectrometry method . Pharmacokinetic analysis conduct use linear log trapezoidal non-compartmental analysis use Phoenix 6.4 .</detailed_description>
	<mesh_term>Hypothyroidism</mesh_term>
	<criteria>age &gt; 21 year time consent euthyroidism undergo treatment LT4 serious illness ability give write informed consent . baseline hematocrit lower 28.0 % TSH great 4.5 mIU/L kidney dysfunction concomitant use drug affect thyroidal axis interaction</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>